FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3038359909> ?p ?o ?g. }

• W3038359909 endingPage "5838" @default.
• W3038359909 startingPage "5827" @default.
• W3038359909 abstract "Purpose Anti-CD19 chimeric antigen receptor T (CAR-T) cell therapy has demonstrated remarkable efficacy for refractory and relapsed diffuse large B cell lymphoma (R/R DLBCL). However, this therapy failed in nearly 25% patients mainly due to antigen loss. The authors performed a phase Ⅱ trial by coadministration of anti-CD19 and anti-CD20 CAR-T cells treatment for R/R DLBCL and evaluated its efficacy and toxicity. Methods Totally 21 patients with DLBCL were enrolled in this study. The patients were conditioned with fludarabine and cyclophosphamide before the infusion of anti-CD19 and anti-CD20 CAR-T cells. Treatment response, toxicity, and persistence were monitored continuously. Results Of the 21 patients received the treatment, the objective response rate (ORR) is 81.0% (95% confidence interval [CI], 58.1%-94.6%) with four cases of bulk (4/5) and one case of testis involvement; 52.4% (95% CI, 29.8%-74.3%) had a complete response (CR). Peak levels of anti-CD19 and anti-CD20 CAR cells were associated with response (P = .007 and .002). Grade 3-4 cytokine release syndrome (CRS) and neurologic events occurred in 28.5% and 9.5% patients, respectively. Median overall survival (OS) and progression-free survival (PFS) were 8.1 and 5.0 months, respectively. The maximum standard uptake value (SUVmax) of CD4/CD8 ratio before and after infusion were associated with responses, and the total lesion glycolysis (TLG) before infusion correlates with cytokines level. Conclusions Coadministration of anti-CD19 and CD20 CAR-T cells therapy for DLBCL is feasible with manageable toxicity. Cytokine markers are related to toxicity and SUVmax could predict efficacy. This trial was registered at www.clinicaltrials.gov as NCT03207178." @default.
• W3038359909 created "2020-07-10" @default.
• W3038359909 creator A5000930830 @default.
• W3038359909 creator A5001560024 @default.
• W3038359909 creator A5001749445 @default.
• W3038359909 creator A5002227916 @default.
• W3038359909 creator A5007120535 @default.
• W3038359909 creator A5020955864 @default.
• W3038359909 creator A5022145759 @default.
• W3038359909 creator A5022581561 @default.
• W3038359909 creator A5023003211 @default.
• W3038359909 creator A5031022736 @default.
• W3038359909 creator A5032062559 @default.
• W3038359909 creator A5032218589 @default.
• W3038359909 creator A5032808067 @default.
• W3038359909 creator A5040655018 @default.
• W3038359909 creator A5043775845 @default.
• W3038359909 creator A5044301848 @default.
• W3038359909 creator A5045094860 @default.
• W3038359909 creator A5045473616 @default.
• W3038359909 creator A5048129965 @default.
• W3038359909 creator A5050692462 @default.
• W3038359909 creator A5056369207 @default.
• W3038359909 creator A5061193945 @default.
• W3038359909 creator A5062545097 @default.
• W3038359909 creator A5066220413 @default.
• W3038359909 creator A5067016617 @default.
• W3038359909 creator A5073663977 @default.
• W3038359909 creator A5074529705 @default.
• W3038359909 creator A5082587315 @default.
• W3038359909 creator A5087585195 @default.
• W3038359909 date "2020-07-01" @default.
• W3038359909 modified "2023-10-14" @default.
• W3038359909 title "Phase II trial of co‐administration of CD19‐ and CD20‐targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma" @default.
• W3038359909 cites W1020989877 @default.
• W3038359909 cites W1049067418 @default.
• W3038359909 cites W1986579589 @default.
• W3038359909 cites W1987759895 @default.
• W3038359909 cites W2006709900 @default.
• W3038359909 cites W2018071905 @default.
• W3038359909 cites W2044947137 @default.
• W3038359909 cites W2082708772 @default.
• W3038359909 cites W2119147717 @default.
• W3038359909 cites W2131395115 @default.
• W3038359909 cites W2133345449 @default.
• W3038359909 cites W2145304413 @default.
• W3038359909 cites W2219506342 @default.
• W3038359909 cites W2305142474 @default.
• W3038359909 cites W2342423058 @default.
• W3038359909 cites W2408097265 @default.
• W3038359909 cites W2412725897 @default.
• W3038359909 cites W2567630865 @default.
• W3038359909 cites W2614435853 @default.
• W3038359909 cites W2752305310 @default.
• W3038359909 cites W2756071038 @default.
• W3038359909 cites W2768823259 @default.
• W3038359909 cites W2773804840 @default.
• W3038359909 cites W2892326722 @default.
• W3038359909 cites W2894051747 @default.
• W3038359909 cites W2903062212 @default.
• W3038359909 cites W2903225254 @default.
• W3038359909 cites W2913160269 @default.
• W3038359909 cites W2965223724 @default.
• W3038359909 doi "https://doi.org/10.1002/cam4.3259" @default.
• W3038359909 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7433814" @default.
• W3038359909 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32608579" @default.
• W3038359909 hasPublicationYear "2020" @default.
• W3038359909 type Work @default.
• W3038359909 sameAs 3038359909 @default.
• W3038359909 citedByCount "31" @default.
• W3038359909 countsByYear W30383599092020 @default.
• W3038359909 countsByYear W30383599092021 @default.
• W3038359909 countsByYear W30383599092022 @default.
• W3038359909 countsByYear W30383599092023 @default.
• W3038359909 crossrefType "journal-article" @default.
• W3038359909 hasAuthorship W3038359909A5000930830 @default.
• W3038359909 hasAuthorship W3038359909A5001560024 @default.
• W3038359909 hasAuthorship W3038359909A5001749445 @default.
• W3038359909 hasAuthorship W3038359909A5002227916 @default.
• W3038359909 hasAuthorship W3038359909A5007120535 @default.
• W3038359909 hasAuthorship W3038359909A5020955864 @default.
• W3038359909 hasAuthorship W3038359909A5022145759 @default.
• W3038359909 hasAuthorship W3038359909A5022581561 @default.
• W3038359909 hasAuthorship W3038359909A5023003211 @default.
• W3038359909 hasAuthorship W3038359909A5031022736 @default.
• W3038359909 hasAuthorship W3038359909A5032062559 @default.
• W3038359909 hasAuthorship W3038359909A5032218589 @default.
• W3038359909 hasAuthorship W3038359909A5032808067 @default.
• W3038359909 hasAuthorship W3038359909A5040655018 @default.
• W3038359909 hasAuthorship W3038359909A5043775845 @default.
• W3038359909 hasAuthorship W3038359909A5044301848 @default.
• W3038359909 hasAuthorship W3038359909A5045094860 @default.
• W3038359909 hasAuthorship W3038359909A5045473616 @default.
• W3038359909 hasAuthorship W3038359909A5048129965 @default.
• W3038359909 hasAuthorship W3038359909A5050692462 @default.
• W3038359909 hasAuthorship W3038359909A5056369207 @default.
• W3038359909 hasAuthorship W3038359909A5061193945 @default.
• W3038359909 hasAuthorship W3038359909A5062545097 @default.

• next